Top Markets
#1 Siacoin Siacoin +30.23%
#2 Official Trump Official Trump +25.53%
#3 Wrapped STX (Velar) Wrapped STX (Velar) +19.32%
#4 EXOD EXOD +18.93%
#5 MowCat MowCat +18.23%
#6 Unit Pump Unit Pump +16.28%
#7 Pump.fun Pump.fun +16.28%
#8 Melania Meme Melania Meme +15.60%
#9 Mubarak Mubarak +14.72%
#10 Wrapped POL Wrapped POL +13.16%
Coin of the day
Siacoin Siacoin
Settings
Language
ENGLISH
Currency
USD
Theme
Mercury Biopharmaceutical Corporation Mercury Biopharmaceutical Corporation

Mercury Biopharmaceutical Corporation

6932
Rank in Stocks #23452
Founded in 2019 and headquartered in New Taipei City, Taiwan, Mercury... Founded in 2019 and headquartered in New Taipei City, Taiwan, Mercury Biopharmaceutical Corporation is dedicated to creating innovative pharmaceutical solutions for medical conditions currently lacking adequate treatment options. A cornerstone of their strategy is the proprietary StackDose platform, an advanced drug development system designed to formulate novel medication delivery methods. This platform facilitates precisely timed drug release, targeted absorption at specific locations within the body, and flexible dosage modifications. The primary objective of StackDose is to significantly boost the bioavailability of active pharmaceutical ingredients, leading to a reduction in required drug dosages and fewer adverse effects. Their development pipeline currently addresses a variety of ailments, such as erectile dysfunction, pulmonary hypertension, sleep disturbances, benign prostatic hyperplasia, angina, migraines, hypertension, and pain management.
Share Price
$0.17616661
Last synced: 2026-08-21
Market Cap
$73.48M
Change (1 day)
0.18%
Change (1 year)
-37.76%
Country
TW
Trade Mercury Biopharmaceutical Corporation (6932)

Category

Healthcare
P/E ratio for Mercury Biopharmaceutical Corporation (6932)
P/E ratio as of 2026 TTM: 0
According to Mercury Biopharmaceutical Corporation latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Mercury Biopharmaceutical Corporation from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
 - -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
 - -
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
 - -
JP
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
 - -
CH
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
 38.29 -
IN
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.